Le Centre Sud dans les médias

Les pays en développement seront les plus touchés en cas de guerre commerciale (économiste)

Entretien avec Martin Khor

French.CHINA.ORG.CN

9 Août 2017

Available at: http://french.china.org.cn/foreign/txt/2017-08/09/content_41378146.htm

 


Trade war would hit developing and poor countries hardest: economist

Interview with Martin Khor

XINHUANET

7 August 2017

Available at: http://news.xinhuanet.com/english/2017-08/07/c_136506428.htm

 


Interview with the South Centre’s Executive Director Martin Khor on the International Financial Crisis from a Southern Perspective

GlobeMagazine

24 July 2017

Available at: http://mp.weixin.qq.com/s/-cc1_zNlsKQYgVrDZxmTTQ

 


Catalyzing the Implementation of NDCs in the Context of the 2030 Agenda through South-South Cooperation

Video interview of Vicente Yu at 01:52

IISD Reporting Services

10 May 2017

Available at: http://enb.iisd.org/videos/climate/unfccc-sb46-env/wednesday-10-may-2017/?autoplay

 


La política climática mundial en vilo

POR MARTIN KHOR

El Telégrafo

10 Mayo 2017

Available at: http://www.eltelegrafo.com.ec/noticias/punto-de-vista/1/la-politica-climatica-mundial-en-vilo

 


Un traité pour réorienter l’industrie pharmaceutique
Vers une recherche sans brevets

PAR GERMÁN VELÁSQUEZ

Face à la cupidité des laboratoires pharmaceutiques, un projet de traité international cherche à découpler le coût de la recherche et le prix des médicaments, afin de faciliter la découverte de remèdes efficaces et accessibles aux populations qui en ont le plus besoin.Même lorsqu’elles ne sont pas solvables. Certains mécanismes permettent d’ores et déjà d’orienter la recherche vers les maladies endémiques au Sud.

Le Monde diplomatique

Avril 2013

Available at: http://intra.mondediplo.net/fich.php/0c5657fb504c590/11_Sciences.pdf

 


SC verdict on Glivec has positive global implications: South Centre

The South Centre, an intergovernmental organisation of developing countries, has welcomed the recent ruling by the Supreme Court, dismissing the petition from Novartis on Glivec and has termed the verdict as a historic decision with positive global implications.

PHARMABIZ.com

6 April 2013

Available at: www.pharmabiz.com/PrintArticle.aspx

 


South Centre hails Indian drug patent decision

From SOUTHNEWS, by Martin Khor:

“The ruling by the Supreme Court of India dismissing the petition from Novartis AG is a historic decision with positive global implications … The Novartis AG application had claimed a patent for a new salt form (imatinib mesylate), a medicine for the treatment of chronic myeloid leukemia. Novartis sells this medicine in several countries under the brand name Glivec (Gleevec). The Indian patent office had rejected the patent application on the ground that the claimed new form was anticipated in a US patent of 1996 for the compound imatinib and that the new form did not enhance the therapeutic efficacy of the drug. The decision was upheld by the Indian Patents Appellate Board (IPAB).

The decision by the Supreme Court of India has significant positive global implications. It has effectively protected the leading role of India in supplying affordable medicines to other developing countries. The reaffirmation of the primacy of health and access to medicines as a right of citizens is particularly important for the international community when these rights are under significant threat under bilateral trade and investment agreements.”

Naked Keynesianism

3 April 2013

Available at: nakedkeynesianism.blogspot.ch/2013/04/south-centre-hails-indian-drug-patent.html

 


Indian court rejects Novartis patent

German Velasquez, a special adviser for health and development at South Centre, a think tank based in Geneva, Switzerland, says he hopes that “many developing countries will follow India’s example to protect the rights of their populations to have access to essential medicines”. A 2011 study by South Centre found evidence of “a significant proliferation of patents on developments of incremental nature” in Argentina, Brazil, Colombia, India and South Africa.

nature

1 April 2013

Available at: www.nature.com/news/indian-court-rejects-novartis-patent-1.12717

 

 


0

Your Cart